Fifth Third Bancorp Acquires 474 Shares of Becton, Dickinson and Company (NYSE:BDX)

Fifth Third Bancorp increased its position in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 1.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,656 shares of the medical instruments supplier’s stock after acquiring an additional 474 shares during the quarter. Fifth Third Bancorp’s holdings in Becton, Dickinson and Company were worth $9,182,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Householder Group Estate & Retirement Specialist LLC bought a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. Indiana Trust & Investment Management CO acquired a new position in Becton, Dickinson and Company during the 3rd quarter valued at approximately $27,000. OFI Invest Asset Management purchased a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at $25,000. CGC Financial Services LLC purchased a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at $37,000. Finally, Fortitude Family Office LLC purchased a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at $35,000. Institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on BDX shares. Raymond James upped their price objective on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Morgan Stanley cut their price objective on shares of Becton, Dickinson and Company from $310.00 to $280.00 and set an “overweight” rating for the company in a research report on Monday, December 4th. Finally, Barclays raised their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, February 5th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $279.17.

Check Out Our Latest Stock Report on BDX

Insiders Place Their Bets

In related news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares in the company, valued at approximately $542,348.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $247.45 on Monday. The firm’s fifty day simple moving average is $239.68 and its 200-day simple moving average is $244.81. The stock has a market capitalization of $71.49 billion, a price-to-earnings ratio of 58.64, a PEG ratio of 2.04 and a beta of 0.42. Becton, Dickinson and Company has a 12 month low of $229.85 and a 12 month high of $287.32. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.08 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last posted its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.73 billion. During the same period last year, the firm posted $2.98 EPS. Becton, Dickinson and Company’s quarterly revenue was up 2.6% on a year-over-year basis. As a group, equities analysts forecast that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 8th were given a dividend of $0.95 per share. The ex-dividend date was Thursday, March 7th. This represents a $3.80 annualized dividend and a dividend yield of 1.54%. Becton, Dickinson and Company’s payout ratio is currently 90.05%.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

See Also

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.